CVRX

CVRx Inc

Add to Watchlist

Advanced Chart

8.340

+0.15(1.832%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

8.450

Open

8.210

VWAP

8.28

Vol

166.90K

Mkt Cap

217.45M

Low

8.100

Amount

1.38M

EV/EBITDA(TTM)

Total Shares

21.60M

164.11M

EV/OCF(TTM)

P/S(TTM)

3.75

CVRx, Inc. is a commercial-stage medical device company. The Company is focused on developing, manufacturing and commercializing advanced neuromodulation solutions for patients with cardiovascular diseases. The Company's integrated platform technology, Barostim, is designed to leverage the power of the brain and nervous system to address the imbalance of the autonomic nervous system (ANS), which causes heart failure with reduced ejection fraction (HFrEF) and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy (BAT) by sending imperceptible and persistent electrical pulses to baroreceptors located in the wall of the carotid artery to signal the brain to modulate cardiovascular function. Barostim is a minimally invasive neuromodulation device that consists of two implantable components, an implantable pulse generator (IPG) and a stimulation lead, and is programmed by a wireless clinician-controlled programmer that communicates with the IPG.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

16.01M

+4.36%

-0.465

+8.24%

14.54M

+8.71%

-0.489

-14.28%

13.22M

+11.94%

-0.520

-19.94%

Estimates Revision

The market is revising Downward the revenue expectations for CVRx, Inc. (CVRX) for FY2025, with the revenue forecasts being adjusted by -7.94% over the past three months. During the same period, the stock price has changed by 10.90%.

Revenue Estimates for FY2025

Revise Downward

-7.94%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-2.12%

In Past 3 Month

Stock Price

Go Up

+10.90%

In Past 3 Month

7 Analyst Rating

51.08% Upside

Wall Street analysts forecast CVRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CVRX is 12.60 USD with a low forecast of 7.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

0 Hold

1 Sell

Moderate Buy

51.08% Upside

Current: 8.340

Low

7.00

Averages

12.60

High

20.00

51.08% Upside

Current: 8.340

Low

7.00

Averages

12.60

High

20.00

JPMorgan

Neutral -> Underweight

downgrade

$15 -> $7

2025-05-09

Reason

JPMorgan

Price Target

$15 -> $7

2025-05-09

downgrade

Neutral -> Underweight

Reason

Piper Sandler

Matt O'Brien

Overweight

downgrade

$20 -> $12

2025-05-09

Reason

Piper Sandler

Matt O'Brien

Price Target

$20 -> $12

2025-05-09

downgrade

Overweight

Reason

Piper Sandler analyst Matt O'Brien lowered the firm's price target on CVRx to $12 from $20 and keeps an Overweight rating on the shares. The firm notes the company reported Q1 results that were in line with the pre-announcement. Management primarily attributed the miss to sales force realignment that was more substantial than initially anticipated. CVRx also lowered full year sales guidance by more than the miss in the quarter. Piper believes the new guidance is fairly set but there is no lay-up as it still anticipates some productivity improvement through year-end.

Canaccord Genuity

William Plovanic

Strong Buy

Maintains

$23 → $18

2025-04-08

Reason

Canaccord Genuity

William Plovanic

Price Target

$23 → $18

2025-04-08

Maintains

Strong Buy

Reason

Canaccord lowered the firm's price target on CVRx to $18 from $23 and keeps a Buy rating on the shares. The firm updated its model to reflect both the Q1/25 revenue miss and a lower outlook for the US given the sales force disruption. They also expect the company to continue to invest in growth and therefore operating expenses will stay similar to pre-release estimates.

Lake Street

Frank Takkinen

Strong Buy

Maintains

$19 → $14

2025-04-08

Reason

Lake Street

Frank Takkinen

Price Target

$19 → $14

2025-04-08

Maintains

Strong Buy

Reason

Canaccord Genuity

William Plovanic

Strong Buy

Maintains

$22 → $23

2025-02-05

Reason

Canaccord Genuity

William Plovanic

Price Target

$22 → $23

2025-02-05

Maintains

Strong Buy

Reason

Piper Sandler

Matt O'Brien

Buy

Maintains

$16 → $20

2025-02-05

Reason

Piper Sandler

Matt O'Brien

Price Target

$16 → $20

2025-02-05

Maintains

Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for CVRx Inc (CVRX.O) is -4.33, compared to its 5-year average forward P/E of -6.25. For a more detailed relative valuation and DCF analysis to assess CVRx Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-6.25

Current PE

-4.33

Overvalued PE

-3.48

Undervalued PE

-9.02

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-5.88

Current EV/EBITDA

-3.80

Overvalued EV/EBITDA

0.22

Undervalued EV/EBITDA

-11.98

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

7.69

Current PS

3.69

Overvalued PS

12.59

Undervalued PS

2.80